Literature DB >> 9118685

Endothelin abnormalities in patients with pulmonary embolism.

M Sofia1, S Faraone, M Alifano, A Micco, R Albisinni, M Maniscalco, G Di Minno.   

Abstract

BACKGROUND: Endothelin (ET) is an endothelium-derived multifunctional peptide involved in the local regulation of the vascular tone. STUDY
OBJECTIVES: To assess changes of endogenous ET production/excretion in the acute phase (36 h from the event) of pulmonary embolism (PE). PARTICIPANTS: Ten patients with acute PE, nine patients with acute lung injury (ALI), and 12 healthy volunteers (HVs). MEASUREMENTS AND
RESULTS: ET was detected by radioimmunoassay in venous and arterial blood as well as in 24-h urine specimens. For each subject, arterial/venous immunoreactive ET (ir-ET) ratio was evaluated as an index of its pulmonary extraction/synthesis. Creatinine clearance was employed in each case to obtain a corrected renal ir-ET clearance. Renal ir-ET clearance was comparable in all three groups. Arterial/venous ir-ET ratio was comparable in PE and in ALI patients (1.31 +/- 0.25 vs 1.24 +/- 0.20; p = 0.7), while it was significantly higher in PE patients than in HV subjects (0.85 +/- 0.07; p = 0.0001). Accordingly, 24-h urine ir-ET excretion was higher in PE (120.50 +/- 27.36 ng/24 h) and ALI patients (135.80 +/- 21.60 ng/24 h) than in HV subjects (68.33 +/- 9.31 ng/24 h; p = 0.0001).
CONCLUSIONS: Abnormalities of ET metabolism-mainly related to increased synthesis and/or defective pulmonary handling-occur in the acute phase of PE. The relevance of this finding with respect to the pathogenesis and/or management of pulmonary thromboembolism remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118685     DOI: 10.1378/chest.111.3.544

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  The effect of a combination of inhaled nitric oxide and an endothelinA-receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism.

Authors:  Ji-Hyun Lee; Sehyun Kim; Byung-Kyu Park; Woo-Sung Kim; Dong-Soon Kim; Won-Dong Kim; Sang-Do Lee
Journal:  Lung       Date:  2005 Mar-Apr       Impact factor: 2.584

2.  Subclinical Atherosclerosis in Patients with Prior Pulmonary Thromboembolism.

Authors:  Zafer Buyukterzi; Meral Buyukterzi; Ercan Kurtipek; Mehmet Sertac Alpaydin; Sukru Karaarslan
Journal:  Med Princ Pract       Date:  2017-04-04       Impact factor: 1.927

3.  Computational models of the pulmonary circulation: Insights and the move towards clinically directed studies.

Authors:  Merryn H Tawhai; Alys R Clark; Kelly S Burrowes
Journal:  Pulm Circ       Date:  2011 Apr-Jun       Impact factor: 3.017

4.  Blood flow redistribution and ventilation-perfusion mismatch during embolic pulmonary arterial occlusion.

Authors:  K S Burrowes; A R Clark; M H Tawhai
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

5.  Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension.

Authors:  Mark Southwood; Robert V MacKenzie Ross; Rhoda E Kuc; Guy Hagan; Karen K Sheares; David P Jenkins; Martin Goddard; Anthony P Davenport; Joanna Pepke-Zaba
Journal:  Life Sci       Date:  2016-02-10       Impact factor: 5.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.